JP2016533395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533395A5 JP2016533395A5 JP2016546183A JP2016546183A JP2016533395A5 JP 2016533395 A5 JP2016533395 A5 JP 2016533395A5 JP 2016546183 A JP2016546183 A JP 2016546183A JP 2016546183 A JP2016546183 A JP 2016546183A JP 2016533395 A5 JP2016533395 A5 JP 2016533395A5
- Authority
- JP
- Japan
- Prior art keywords
- specific binding
- binding member
- her2
- cancer
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009870 specific binding Effects 0.000 claims 33
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 23
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 12
- 230000027455 binding Effects 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 101150054472 HER2 gene Proteins 0.000 claims 8
- 108700020302 erbB-2 Genes Proteins 0.000 claims 8
- 239000002299 complementary DNA Substances 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 238000003365 immunocytochemistry Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1317622.7A GB201317622D0 (en) | 2013-10-04 | 2013-10-04 | Cancer biomarkers and uses thereof |
| GB1317622.7 | 2013-10-04 | ||
| PCT/GB2014/052994 WO2015049537A1 (en) | 2013-10-04 | 2014-10-03 | Cancer biomarkers and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533395A JP2016533395A (ja) | 2016-10-27 |
| JP2016533395A5 true JP2016533395A5 (https=) | 2018-08-09 |
| JP6449308B2 JP6449308B2 (ja) | 2019-01-09 |
Family
ID=49630223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546183A Expired - Fee Related JP6449308B2 (ja) | 2013-10-04 | 2014-10-03 | がんバイオマーカー及びその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160289336A1 (https=) |
| EP (1) | EP3052647B1 (https=) |
| JP (1) | JP6449308B2 (https=) |
| KR (1) | KR20160092992A (https=) |
| CN (1) | CN105722997A (https=) |
| AU (1) | AU2014330942A1 (https=) |
| BR (1) | BR112016007348A2 (https=) |
| CA (1) | CA2925186A1 (https=) |
| CL (1) | CL2016000777A1 (https=) |
| DK (1) | DK3052647T3 (https=) |
| EA (1) | EA201690450A1 (https=) |
| ES (1) | ES2687783T3 (https=) |
| GB (1) | GB201317622D0 (https=) |
| HR (1) | HRP20181566T1 (https=) |
| IL (1) | IL244510A0 (https=) |
| LT (1) | LT3052647T (https=) |
| MX (1) | MX2016004286A (https=) |
| PE (1) | PE20160950A1 (https=) |
| SG (1) | SG11201602605TA (https=) |
| WO (1) | WO2015049537A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103555733A (zh) | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TW201642897A (zh) * | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| KR20190022632A (ko) | 2016-06-20 | 2019-03-06 | 에프-스타 베타 리미티드 | Lag-3 결합 구성원 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| CN107868814A (zh) * | 2017-12-19 | 2018-04-03 | 威海威仕泰医疗科技有限公司 | 一种用于检测HER2基因的Dig标记探针的制备方法 |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3774902A1 (en) | 2018-04-02 | 2021-02-17 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| KR20210028155A (ko) * | 2018-05-17 | 2021-03-11 | 이뮤놈 인코포레이티드 | Ch3 도메인 에피토프 태그 |
| CN108875302B (zh) * | 2018-06-22 | 2022-02-22 | 广州漫瑞生物信息技术有限公司 | 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| KR102325731B1 (ko) * | 2020-01-15 | 2021-11-15 | 주식회사 베르티스 | 암의 진단용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103555733A (zh) * | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| EP3241842B1 (en) * | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| EP2435071A1 (en) * | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
-
2013
- 2013-10-04 GB GBGB1317622.7A patent/GB201317622D0/en not_active Ceased
-
2014
- 2014-10-03 LT LTEP14781645.8T patent/LT3052647T/lt unknown
- 2014-10-03 CA CA2925186A patent/CA2925186A1/en not_active Abandoned
- 2014-10-03 JP JP2016546183A patent/JP6449308B2/ja not_active Expired - Fee Related
- 2014-10-03 CN CN201480055024.5A patent/CN105722997A/zh active Pending
- 2014-10-03 WO PCT/GB2014/052994 patent/WO2015049537A1/en not_active Ceased
- 2014-10-03 EP EP14781645.8A patent/EP3052647B1/en active Active
- 2014-10-03 HR HRP20181566TT patent/HRP20181566T1/hr unknown
- 2014-10-03 ES ES14781645.8T patent/ES2687783T3/es active Active
- 2014-10-03 SG SG11201602605TA patent/SG11201602605TA/en unknown
- 2014-10-03 KR KR1020167011055A patent/KR20160092992A/ko not_active Withdrawn
- 2014-10-03 DK DK14781645.8T patent/DK3052647T3/en active
- 2014-10-03 EA EA201690450A patent/EA201690450A1/ru unknown
- 2014-10-03 PE PE2016000450A patent/PE20160950A1/es not_active Application Discontinuation
- 2014-10-03 BR BR112016007348A patent/BR112016007348A2/pt not_active Application Discontinuation
- 2014-10-03 AU AU2014330942A patent/AU2014330942A1/en not_active Abandoned
- 2014-10-03 MX MX2016004286A patent/MX2016004286A/es unknown
-
2016
- 2016-03-08 IL IL244510A patent/IL244510A0/en unknown
- 2016-03-31 US US15/087,272 patent/US20160289336A1/en not_active Abandoned
- 2016-04-04 CL CL2016000777A patent/CL2016000777A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533395A5 (https=) | ||
| DK2556091T3 (en) | Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies to treat diseases associated with unwanted cell proliferation | |
| JP2014524746A5 (https=) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| KR102571924B1 (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| JP2021516057A5 (https=) | ||
| JP2012012402A5 (https=) | ||
| Wu et al. | The non-coding RNA llme23 drives the malignant property of human melanoma cells | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| DK1937815T3 (en) | Methods and compositions for the modulation of tumor cell activity | |
| JP2015533788A5 (https=) | ||
| JP2019511904A5 (https=) | ||
| JP2016536330A5 (https=) | ||
| JP2018518152A5 (https=) | ||
| JP2018511319A5 (https=) | ||
| JP2017530691A5 (https=) | ||
| JP2014518615A5 (https=) | ||
| JP2012019790A5 (https=) | ||
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| JP2016539083A5 (https=) | ||
| JP2011509246A5 (https=) | ||
| JP2017538439A5 (https=) | ||
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| JPWO2021075545A5 (https=) | ||
| JP2016514130A5 (https=) |